Oncolytics Biotech stock jumps on FDA meeting plans for trial By Investing.com
Oncolytics Biotech (NASDAQ:ONCY) shares rose about 5.9% premarket after the company said it will hold a Type D meeting with the FDA in the first half of August to discuss a registrational pathway for its REO 033 trial. It plans to add Part B to support potential accelerated and full approval of pelareorep. Part A enrollment targets 60 patients, with sites activating through July and August.
How this was made
The 30-second read
Why it matters
The disclosed Type D meeting and proposed Part B addition aim to preserve REO 033’s core design while enabling randomized efficacy data and potentially supporting accelerated and full approval discussions.
Market read
Traders can reassess regulatory and development risk for pelareorep based on the timing and structure of the planned FDA discussion and the company’s stated clinical milestones.
What to watch
Key uncertainty remains whether FDA agrees with the registrational pathway and whether Part A tumor response and site activation timelines translate into sufficient randomized efficacy for Part B.
Background
Oncolytics is running REO 033 for pelareorep in RAS-mutant, microsatellite stable metastatic colorectal cancer, building on prior REO 022 results and Fast Track designation.
Ticker impact
Oncolytics said it will hold an FDA Type D meeting in early August to discuss a registrational pathway for its REO 033 trial, including adding Part B.
Likely continued upside bias while traders price in FDA feedback and Part B feasibility; volatility elevated into the August meeting.
The article discloses a concrete regulatory interaction (Type D meeting timing) and specific trial modification (adding Part B) plus a stated timeline for Part A updates and potential Part B enrollment.
Market effects
Reinforces that RAS-mutant MSS metastatic colorectal cancer immunotherapy programs may pursue registrational pathways via trial design expansion and FDA feedback.
Limited, primarily US biotech sentiment tied to FDA interaction expectations.
Moderate, as FDA pathway clarity can influence global investor perception of similar oncology development strategies.
Counterpoint
A planned FDA meeting is not approval; traders may overreact to process milestones before seeing efficacy signals from Part A or concrete FDA guidance.
Key entities
- companyOncolytics Biotech Inc
NASDAQ-listed clinical-stage biotech developing pelareorep; subject of the FDA meeting and trial design update.
- regulatorFDA
Will meet with Oncolytics to discuss a potential registrational pathway for REO 033, including adding Part B.
- clinical_trialREO 033
Pelareorep trial design being expanded with Part B to support potential registrational use.
- drugpelareorep
Investigational immunotherapy for RAS-mutant, MSS metastatic colorectal cancer.
